CLRB Cellectar Biosciences, Inc.

NASDAQ
$1.80

Cellectar Biosciences, Inc. (CLRB) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.46 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -28.3% since its last earnings release on August 13, 2026.

Cellectar Biosciences Missed Consensus Estimates
Thursday, August 13, 2026 · 7:15 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 7:15 AM ET
Earnings Whisper
-
vs ($0.46)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.39

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.